ondansetron has been researched along with Blood Diseases in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kosmidis, PA | 1 |
| Kalofonos, HP | 1 |
| Christodoulou, C | 1 |
| Syrigos, K | 1 |
| Makatsoris, T | 1 |
| Skarlos, D | 1 |
| Bakogiannis, C | 1 |
| Nicolaides, C | 1 |
| Bafaloukos, D | 1 |
| Bamias, A | 1 |
| Samantas, E | 1 |
| Xiros, N | 1 |
| Boukovinas, I | 1 |
| Fountzilas, G | 1 |
| Dimopoulos, MA | 1 |
1 trial available for ondansetron and Blood Diseases
| Article | Year |
|---|---|
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2008 |